ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat - PubMed (original) (raw)
ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat
V S DiCarlo et al. Am J Physiol. 1995 Nov.
Abstract
The selective endothelin-A (ETA)-receptor antagonist BQ-123 has been shown to prevent chronic hypoxia-induced pulmonary hypertension in the rat. Therefore in the current study we utilized BQ-123 to test the hypothesis that blockade of the ETA receptor can reverse as well as prevent the increase in mean pulmonary artery pressure, right ventricle-to-left ventricle plus septum ratio, and percent wall thickness in small (50-100 microns) pulmonary arteries observed in male Sprague-Dawley rats exposed to normobaric hypoxia (10% O2, 2 wk). Infusion of BQ-123 (0.4 mg.0.5 microliter-1.h-1 for 2 wk in 10% O2) begun after 2 wk of hypoxia significantly reversed the established pulmonary hypertension and prevented further progression of right ventricular hypertrophy during the third and fourth week of hypoxia. BQ-123 infusion instituted before exposure to hypoxia completely prevented the hypoxia-induced pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular remodeling. These findings suggest that, in the lung, hypoxia induced an increase synthesis of endothelin-1, which acts locally on ETA receptors to cause pulmonary hypertension, right heart hypertrophy, and pulmonary vascular remodeling, while ETA-receptor blockade can both prevent and reverse these processes.
Similar articles
- Endothelin-A receptor antagonist prevents acute hypoxia-induced pulmonary hypertension in the rat.
Oparil S, Chen SJ, Meng QC, Elton TS, Yano M, Chen YF. Oparil S, et al. Am J Physiol. 1995 Jan;268(1 Pt 1):L95-100. doi: 10.1152/ajplung.1995.268.1.L95. Am J Physiol. 1995. PMID: 7840234 - The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.
Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J, DiCarlo VS, Oparil S. Chen SJ, et al. J Cardiovasc Pharmacol. 1997 Jun;29(6):713-25. doi: 10.1097/00005344-199706000-00003. J Cardiovasc Pharmacol. 1997. PMID: 9234651 - [Effects of endothelin receptor antagonist on the hypoxic pulmonary hypertension].
Chen W, Cheng D. Chen W, et al. Hua Xi Yi Ke Da Xue Xue Bao. 2000 Sep;31(3):370-2, 386. Hua Xi Yi Ke Da Xue Xue Bao. 2000. PMID: 12545837 Chinese. - Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
Holm P. Holm P. Scand Cardiovasc J Suppl. 1997;46:1-40. Scand Cardiovasc J Suppl. 1997. PMID: 9265559 Review. - Endothelin and pulmonary hypertension.
Chen YF, Oparil S. Chen YF, et al. J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S49-53. doi: 10.1097/00005344-200000002-00012. J Cardiovasc Pharmacol. 2000. PMID: 10976782 Review.
Cited by
- Endothelin-1 mediates hypoxia-induced increases in vascular collagen in the newborn mouse lung.
Ambalavanan N, Li P, Bulger A, Murphy-Ullrich J, Oparil S, Chen YF. Ambalavanan N, et al. Pediatr Res. 2007 May;61(5 Pt 1):559-64. doi: 10.1203/pdr.0b013e318045beae. Pediatr Res. 2007. PMID: 17413856 Free PMC article. - The PPARγ ligand rosiglitazone attenuates hypoxia-induced endothelin signaling in vitro and in vivo.
Kang BY, Kleinhenz JM, Murphy TC, Hart CM. Kang BY, et al. Am J Physiol Lung Cell Mol Physiol. 2011 Dec;301(6):L881-91. doi: 10.1152/ajplung.00195.2011. Epub 2011 Sep 16. Am J Physiol Lung Cell Mol Physiol. 2011. PMID: 21926265 Free PMC article. - Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha.
Yu AY, Shimoda LA, Iyer NV, Huso DL, Sun X, McWilliams R, Beaty T, Sham JS, Wiener CM, Sylvester JT, Semenza GL. Yu AY, et al. J Clin Invest. 1999 Mar;103(5):691-6. doi: 10.1172/JCI5912. J Clin Invest. 1999. PMID: 10074486 Free PMC article. - Elevated mean arterial pressure in the ovariectomized rat was normalized by ET(A) receptor antagonist therapy: absence of cardiac hypertrophy and fibrosis.
Mercier I, Pham-Dang M, Clement R, Gosselin H, Colombo F, Rouleau JL, Calderone A. Mercier I, et al. Br J Pharmacol. 2002 Jul;136(5):685-92. doi: 10.1038/sj.bjp.0704765. Br J Pharmacol. 2002. PMID: 12086977 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical